Authors


Sheryl Stevenson

Latest:

CTS 2025: Christine Kay, MD, on OPGx-LCA5 clinical results translated into real-life changes

Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.


John H. Merey, MD

Latest:

Ophthalmologist shares his story on Holocaust Remembrance Day

John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.


Caesar K. Luo, MD, FACS, FASRS

Latest:

Searching for durable therapies for diabetic macular edema amid the pandemic

Patients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.


Kassi Filkins

Latest:

Nanoscope announces formation of Vision Advisory Committee

Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration.



Albert J. Augustin, MD

Latest:

Optimizing Care For Patients With Retinal Disorders

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.


Michael A. Singer, MD

Latest:

Exploring cryopreserved amniotic membrane following intravitreal injection

CAM encourages corneal healing in patients with ocular surface disease.


David Lally, MD

Latest:

Sustained-release anti-inflammatory therapy is valuable in noninfectious uveitis

Long-term sustained-release therapy pays off in management of chronic, vision-threatening disease.



John Kitchens, MD

Latest:

Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.


Carolyn Majcher, OD, FAAO

Latest:

DR/DME: Ongoing Clinical Trials and New Diagnostic Tools

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).


Alessandro Berni, MD

Latest:

New guidelines boost choriocapillaris imaging in AMD with SS-OCTA

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.


Advertorial

Latest:

Broadening the benefits of iCare EIDON retinal imaging with the new Ultra-Wide Field Module

This article is produced by iCare Finland for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.



Fred Crawford, MD

Latest:

Successful treatment of bilateral diffuse Uveal melanocytic proliueration with plasmapheresis

Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.


Patrizia Busatto, MD

Latest:

IOL designed for AMD offers hope for patients

Examining an intraocular implant that can sharpen vision for patients as disease progresses.


Dilsher S. Dhoot, MD

Latest:

Rapid Improvements In DME With Next-Generation Anti-VEGF Therapies: Case Highlights

Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF agents like aflibercept 8 mg and faricimab demonstrate significant efficacy in treating diabetic macular edema (DME), allowing for extended treatment intervals of 9 to 10 weeks compared to monthly dosing with earlier agents, while improving anatomic outcomes and visual acuity.


Victor Gonzalez, MD

Latest:

Victor Gonzalez, MD, shares research findings on vision restoration in patients with retinitis pigmentosa

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).


Robin Vora, MD

Latest:

The future of retina: New targets and more durable solutions

Among the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition.


Tunde Peto, MD, PhD

Latest:

Creating the best care environment for patients with diabetic eye disease

Tunde Peto, MD, PhD, discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.


Daniel F. Kiernan, MD, FACS

Latest:

Why wait? The data show administering steroids to DME patients with good vision leads to long-term success

A review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.


Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences

Latest:

Saving the world: Pharmaceutical innovation in nine months

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.


Jean-Francois Korobelnik, MD

Latest:

Optimizing Care For Patients With Retinal Disorders

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.


Jennifer Lim, MD, FARVO, FASRS

Latest:

ARVO 2025: Early intervention is crucial for patients with sickle cell retinopathy

Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation.


Ashkan Abbey, MD

Latest:

Expert insights: Ashkan Abbey, MD discusses 1-year results of DAVIO-2 trial

Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.


George Magrath, MD

Latest:

Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disorders

The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.


Laird Harrison

Latest:

Microaneurysm turnover predicts diabetic retinopathy progression

Micoaneurysm turnover in the early stages of diabetic retinopathy predicts how much the disease will progress, according to researchers.



Professor William Ayliffe

Latest:

Electroretinography: Out of the laboratory and into the clinic

OCT has many benefits, yet falls short of reliably diagnosing and managing retinopathies and glaucoma. ERG remains the stalwart method for this application and this article highlights how technological advancements have enabled its introduction to the clinic.


Julianne Mobilian

Latest:

ASRS 2019 Street Team: W. Lloyd Clark, MD

ICYMI: Dr. Clark breaks down the results of the PANORAMA Study

© 2025 MJH Life Sciences

All rights reserved.